Ocular infections caused by non-tuberculous mycobacteria: update on epidemiology and management

Clin Exp Ophthalmol. 2012 Jul;40(5):467-75. doi: 10.1111/j.1442-9071.2011.02679.x. Epub 2011 Nov 4.

Abstract

Background: To provide an update on the frequency, distribution, risk factors and in vitro susceptibility of ocular infections caused by non-tuberculous mycobacteria.

Design: Retrospective study of university clinic patients.

Participants: One hundred thirty-nine patients with culture confirmed non-tuberculous mycobacteria infections seen at Bascom Palmer Eye Institute from January 1980 to July 2007.

Methods: Chart review of data collected included patients' demographics, risk factors, microbiological profiles and clinical outcomes.

Main outcome measures: Frequency, distribution, risk factors and in vitro susceptibility of ocular infections caused by non-tuberculous mycobacteria.

Results: A total of 183 non-tuberculous mycobacteria isolates from 142 eyes were identified, with a fourfold increase in the number of eyes infected with non-tuberculous mycobacteria from 1980-1989 (13.4%) to 2000-2007 (56.3%). Eighty-three percent of non-tuberculous mycobacteria isolates were identified as M. abscessus/chelonae. The majority (91%) of isolates were recovered within 10 days. Common diagnoses included keratitis (36.6%), scleral buckle infections (14.8%) and socket/implant infections (14.8%). Identifiable risk factors were presence of biomaterials (63.1%), ocular surgery (24.1%) and steroid exposure (77%). The median time from diagnosis of culture positive non-tuberculous mycobacteria infection to resolution was 13 to 24 weeks. Combination therapy was used to treat 80% of infected eyes. In vitro susceptibility of non-tuberculous mycobacteria isolates were: amikacin, 81%; clarithromycin, 93%; and moxifloxacin, 21%.

Conclusions: The incidence of ocular infections caused by non-tuberculous mycobacteria has increased within the last 8 years, with a high number of biomaterial associated infections among this group. Clinical diagnosis and microbiological confirmation of non-tuberculous mycobacteria infections remains challenging. Patient outcomes may be improved by early diagnosis, appropriate therapy and removal of biomaterials.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Amikacin / therapeutic use
  • Anti-Bacterial Agents / therapeutic use
  • Aza Compounds / therapeutic use
  • Child
  • Child, Preschool
  • Clarithromycin / therapeutic use
  • Combined Modality Therapy
  • Corneal Ulcer / drug therapy
  • Corneal Ulcer / epidemiology
  • Corneal Ulcer / microbiology
  • Eye Infections, Bacterial / epidemiology*
  • Eye Infections, Bacterial / microbiology
  • Eye Infections, Bacterial / therapy
  • Female
  • Florida / epidemiology
  • Fluoroquinolones
  • Humans
  • Incidence
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Moxifloxacin
  • Mycobacterium Infections, Nontuberculous / epidemiology*
  • Mycobacterium Infections, Nontuberculous / microbiology
  • Mycobacterium Infections, Nontuberculous / therapy
  • Nontuberculous Mycobacteria / isolation & purification*
  • Ophthalmologic Surgical Procedures
  • Quinolines / therapeutic use
  • Retrospective Studies
  • Risk Factors
  • Surgical Wound Infection / drug therapy
  • Surgical Wound Infection / epidemiology
  • Surgical Wound Infection / microbiology
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Aza Compounds
  • Fluoroquinolones
  • Quinolines
  • Amikacin
  • Clarithromycin
  • Moxifloxacin